The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions
36 Pages Posted: 8 Mar 2005 Last revised: 14 Nov 2022
Date Written: February 2005
Abstract
Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have contributed numerous insights and findings to the literature, relied upon ad hoc reduced-form model specifications. In the current paper we take a very different approach: a prospective micro-simulation approach. Using Monte Carlo techniques we model how future price controls in the U.S. will impact early-stage product development decisions in the pharmaceutical industry. This is done within the context of a net present value (NPV) framework that appropriately reflects the uncertainty associated with R&D project technical success, development costs, and future revenues. Using partial-information estimators calibrated with the most contemporary clinical and economic data available, we demonstrate how pharmaceutical price controls will significantly diminish the incentives to undertake early-stage R&D investment. For example, we estimate that cutting prices by 40 to 50 percent in the U.S. will lead to between 30 to 60 percent fewer R&D projects being undertaken (in early-stage development). Given the recent legislative efforts to control prescription drug prices in the U.S., and the likelihood that price controls will prevail as a result, it is important to better understand the firm response to such a regulatory change.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth
-
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
-
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
-
Managed Care, Drug Benefits and Mortality: An Analysis of the Elderly
-
"Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare
By James W. Hughes, Michael J. Moore, ...
-
Intellectual Property and Marketing
By Darius N. Lakdawalla, Tomas Philipson, ...
-
The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output